EP3325016C0 - Pharmaceutical composition comprising an adenoviral vector - Google Patents
Pharmaceutical composition comprising an adenoviral vectorInfo
- Publication number
- EP3325016C0 EP3325016C0 EP16751192.2A EP16751192A EP3325016C0 EP 3325016 C0 EP3325016 C0 EP 3325016C0 EP 16751192 A EP16751192 A EP 16751192A EP 3325016 C0 EP3325016 C0 EP 3325016C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- adenoviral vector
- adenoviral
- vector
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1513010.7A GB201513010D0 (en) | 2015-07-23 | 2015-07-23 | Novel formulation |
PCT/EP2016/067280 WO2017013169A1 (en) | 2015-07-23 | 2016-07-20 | Pharmaceutical composition comprising an adenoviral vector |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3325016A1 EP3325016A1 (en) | 2018-05-30 |
EP3325016C0 true EP3325016C0 (en) | 2023-12-20 |
EP3325016B1 EP3325016B1 (en) | 2023-12-20 |
Family
ID=54106515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16751192.2A Active EP3325016B1 (en) | 2015-07-23 | 2016-07-20 | Pharmaceutical composition comprising an adenoviral vector |
Country Status (11)
Country | Link |
---|---|
US (1) | US10722470B2 (en) |
EP (1) | EP3325016B1 (en) |
JP (1) | JP6797891B2 (en) |
CN (1) | CN108025081B (en) |
AR (2) | AR105401A1 (en) |
BE (1) | BE1023537B1 (en) |
BR (1) | BR112018001260A2 (en) |
CA (1) | CA2992922A1 (en) |
GB (1) | GB201513010D0 (en) |
MX (1) | MX2018001006A (en) |
WO (1) | WO2017013169A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11047534B2 (en) | 2016-01-28 | 2021-06-29 | EcoSense Lighting, Inc. | Multizone mixing cup illumination system |
JP2020537525A (en) * | 2017-10-16 | 2020-12-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Replicative adenovirus vector |
EP3720500A4 (en) * | 2017-12-05 | 2021-08-25 | Applied Genetic Technologies Corporation | Formulation optimization for viral particles |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
WO2019202083A1 (en) * | 2018-04-20 | 2019-10-24 | Laboratorio Reig Jofré, S.A. | Stable adenovirus compositions |
EP3587581A1 (en) * | 2018-06-26 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Formulations for simian adenoviral vectors having enhanced storage stability |
CN109055432B (en) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | Lentivirus infection reagent and preparation method and application thereof |
EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
WO2022067273A1 (en) * | 2020-09-24 | 2022-03-31 | Nant Holdings Ip, Llc | Vaccine compositions for mucosal immune response |
WO2022101461A1 (en) * | 2020-11-16 | 2022-05-19 | BioNTech SE | Enhanced formulation stabilization and improved lyophilization processes |
CN114903922B (en) * | 2021-02-09 | 2024-04-26 | 武汉博沃生物科技有限公司 | Pharmaceutical formulations comprising adenoviruses and methods of preserving same |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
CN115554418B (en) * | 2022-11-22 | 2023-04-14 | 四川至善唯新生物科技有限公司 | Pharmaceutical composition of recombinant adeno-associated virus vector and application thereof |
WO2024112230A1 (en) * | 2022-11-24 | 2024-05-30 | Joint Stock Company "Biocad" | Pharmaceutical composition of non-enveloped virus |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
CA2553541C (en) * | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
DE602005022895D1 (en) * | 2004-08-12 | 2010-09-23 | Schering Corp | STABLE PEGYLATED INTERFERON FORMULATION |
KR20080071192A (en) * | 2005-11-22 | 2008-08-01 | 와이어쓰 | Immunoglobulin fusion protein formulations |
CN1883707A (en) * | 2006-05-19 | 2006-12-27 | 吉林大学 | Lyophilized preparation of recombinant adenovirus and preparation method thereof |
EP2552478B1 (en) * | 2010-03-31 | 2016-12-21 | Stabilitech Ltd. | Excipients for stabilising viral particles |
AU2011336410B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
CN104379733B (en) * | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | Tool changes the recombinant adenovirus group of end |
US8932607B2 (en) * | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
WO2015040234A1 (en) * | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
GB201701239D0 (en) * | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
-
2015
- 2015-07-23 GB GBGB1513010.7A patent/GB201513010D0/en not_active Ceased
-
2016
- 2016-07-20 WO PCT/EP2016/067280 patent/WO2017013169A1/en active Application Filing
- 2016-07-20 US US15/746,473 patent/US10722470B2/en active Active
- 2016-07-20 BR BR112018001260A patent/BR112018001260A2/en active Search and Examination
- 2016-07-20 CA CA2992922A patent/CA2992922A1/en active Pending
- 2016-07-20 EP EP16751192.2A patent/EP3325016B1/en active Active
- 2016-07-20 BE BE2016/5605A patent/BE1023537B1/en not_active IP Right Cessation
- 2016-07-20 MX MX2018001006A patent/MX2018001006A/en unknown
- 2016-07-20 JP JP2018503207A patent/JP6797891B2/en active Active
- 2016-07-20 AR ARP160102193A patent/AR105401A1/en unknown
- 2016-07-20 CN CN201680054923.2A patent/CN108025081B/en active Active
-
2021
- 2021-01-20 AR ARP210100121A patent/AR121079A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
BE1023537B1 (en) | 2017-04-26 |
GB201513010D0 (en) | 2015-09-09 |
EP3325016B1 (en) | 2023-12-20 |
JP6797891B2 (en) | 2020-12-09 |
WO2017013169A1 (en) | 2017-01-26 |
AR121079A2 (en) | 2022-04-13 |
US10722470B2 (en) | 2020-07-28 |
EP3325016A1 (en) | 2018-05-30 |
CN108025081A (en) | 2018-05-11 |
BR112018001260A2 (en) | 2018-09-11 |
CN108025081B (en) | 2021-11-02 |
CA2992922A1 (en) | 2017-01-26 |
AR105401A1 (en) | 2017-09-27 |
MX2018001006A (en) | 2018-06-06 |
US20180214379A1 (en) | 2018-08-02 |
JP2018521078A (en) | 2018-08-02 |
BE1023537A1 (en) | 2017-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3325016C0 (en) | Pharmaceutical composition comprising an adenoviral vector | |
HK1258509A1 (en) | Gitr agonists | |
EP3270960A4 (en) | Vector formulations | |
GB201520559D0 (en) | Peptides | |
IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
GB201521462D0 (en) | Pharmaceutical composition | |
GB201520536D0 (en) | Peptides | |
HK1257745A1 (en) | Peptide composition | |
SG11201705543VA (en) | Sulfonamide pharmaceutical composition | |
GB201520545D0 (en) | Peptides | |
GB201520546D0 (en) | Peptides | |
GB201520563D0 (en) | Peptides | |
GB201519326D0 (en) | Composition` | |
GB201515310D0 (en) | Pharmaceutical composition | |
GB201520862D0 (en) | Pharmaceutical composition | |
GB201520543D0 (en) | Peptides | |
GB201520550D0 (en) | Peptides | |
GB201520541D0 (en) | Peptides | |
GB201520539D0 (en) | Peptides | |
GB201520562D0 (en) | Peptides | |
GB201520567D0 (en) | Peptides | |
GB201520544D0 (en) | Peptides | |
GB201520548D0 (en) | Peptides | |
GB201520542D0 (en) | Peptides | |
GB201520566D0 (en) | Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180216 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190909 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230224 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230619 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016084840 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20240115 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240124 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240321 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240321 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240320 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 |